HUMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Humacyte, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.40−0.03 (-6.50%)
Close on Oct 19, 2026
- Market cap
- $93.93M
- P/E (TTM)
- –
- Dividend yield
- –
Humacyte statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Humacyte | Industry median |
|---|---|---|
| Market Cap | $111.43M | $166.30M |
| Enterprise Value | $31.52M | $88.19M |
| PS Ratio | 52.53 | 3.65 |
| PB Ratio | 3.56 | 2.03 |
| P/TBV Ratio | 3.56 | 2.29 |
Enterprise value
| Measure | Humacyte | Industry median |
|---|---|---|
| EV / Sales | 14.86 | 2.51 |
Income (trailing twelve months)
| Measure | Humacyte | Industry median |
|---|---|---|
| Revenue | $2.12M | $58.34M |
| Gross Profit | -$10.49M | $105.94M |
| Operating Income | -$111.16M | -$21.40M |
| Net Income | -$96.74M | -$22.46M |
| EBITDA | -$111.16M | -$16.91M |
| EPS (Diluted) | -$0.49 | -$0.83 |
Margins
| Measure | Humacyte | Industry median |
|---|---|---|
| Gross Margin | -494.6% | 52.9% |
| Operating Margin | -5240.8% | -44.0% |
| Profit Margin | -4560.8% | -40.2% |
| EBITDA Margin | -5240.8% | -30.2% |
| FCF Margin | -4599.7% | -9.27% |
Returns
| Measure | Humacyte | Industry median |
|---|---|---|
| Return on Equity (ROE) | -547.9% | -53.2% |
| Return on Assets (ROA) | -69.9% | -40.9% |
| Return on Capital Employed (ROCE) | -90.3% | -38.1% |
Growth
| Measure | Humacyte | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 159.3% | 5.96% |
Balance sheet
| Measure | Humacyte | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $79.90M | $61.43M |
| Net Cash (Debt) | $79.90M | $15.35M |
| Net Cash Per Share | $0.29 | $0.66 |
| Equity (Book Value) | $31.26M | $49.09M |
| Book Value Per Share | $0.11 | $1.37 |
| Tangible Book Value | $31.26M | $23.52M |
| Working Capital | $77.84M | $76.81M |
Financial position
| Measure | Humacyte | Industry median |
|---|---|---|
| Current Ratio | 6.21 | 3.34 |
| Quick Ratio | 5.37 | 2.44 |
| Interest Coverage | -10.80 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Humacyte | Industry median |
|---|---|---|
| Operating Cash Flow | -$97.19M | -$12.35M |
| Capital Expenditures | -$367.00K | -$1.08M |
| Free Cash Flow | -$97.56M | -$20.22M |
| FCF Per Share | -$0.35 | -$0.42 |
Efficiency
| Measure | Humacyte | Industry median |
|---|---|---|
| Asset Turnover | 0.02 | 0.39 |
| Inventory Turnover | 1.40 | 2.70 |
| Revenue Per Employee | $11.53K | $404.87K |
| Profits Per Employee | -$525.73K | -$703.34K |
| Employee Count | 184 | 74 |
Dividends and yields
| Measure | Humacyte | Industry median |
|---|---|---|
| Earnings Yield | -86.8% | -23.3% |
| FCF Yield | -87.6% | -8.72% |
Shares
| Measure | Humacyte | Industry median |
|---|---|---|
| Shares Outstanding | 277,798,000 | 58,127,000 |
| Shares Change (YoY) | 45.7% | 10.9% |
| Shares Change (QoQ) | 25.1% | 0.54% |
| Float | 255,655,000 | 49,136,700 |
| Shares Held by Insiders | 7.97% | 11.6% |
| Shares Held by Institutions | 26.4% | 59.4% |
Taxes
| Measure | Humacyte | Industry median |
|---|---|---|
| Income Tax | $0 | $79.87K |
Scores
| Measure | Humacyte | Industry median |
|---|---|---|
| Altman Z-Score | -9.26 | -0.22 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Humacyte's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.